文献速递免疫规划传染病防控与疫情报告妇幼与学校卫生

乌干达9-23月龄儿童黄热病疫苗1/5与1/2剂次安全性最终报告

Adverse events following immunization (AEFI) with fractional one-fifth and one-half doses of yellow fever vaccine compared to standard dose in children 9-23 months old in Uganda, 2019-2022 - final report.
PubMed 文献 · Vaccine · 2026-01-08

在乌干达三个研究点开展单盲随机对照试验,纳入9-23月龄健康儿童,比较BioManguinhos 17DD黄热病疫苗1/2剂、1/5剂与全剂的免疫后不良事件。1770名儿童中1066名(60%)报告至少一种非严重不良事件,发热与腹泻各占34%;严重不良事件30例(1.7%),各组无差异,未发现非预期安全性问题。

要点

  • 1/2剂与1/5剂黄热病疫苗在9-23月龄儿童中未发现非预期安全性问题。
  • 全剂组发热率统计学上高于两个分剂组,发热与腹泻均于接种后第2天达峰。
  • 严重不良事件报告率1.7%,各组无差异,其中3例被因果委员会判定为疫苗产品相关。

核心结论

  • 9-23月龄儿童接种黄热病疫苗1/2剂、1/5剂或全剂均未发现非预期安全性问题,疫苗相关严重不良事件罕见。

研究设计与样本

  • 在乌干达三个研究点开展单盲随机对照试验,招募9-23月龄健康儿童,比较BioManguinhos 17DD黄热病疫苗1/2剂、1/5剂与全剂的安全性。
  • 共1770名儿童入组,免疫后28天主动监测不良事件,前14天使用日记卡与体温计记录,严重不良事件由乌干达AEFI委员会独立团队调查。

主要发现

  • 1770名入组儿童中1066名(60%)报告至少一种非严重不良事件,最常见为发热610例(34%)与腹泻608例(34%)。
  • 发热与腹泻患病率均于接种后第2天达峰,全剂组发热患病率统计学上高于两个分剂组。
  • 30名参与者(1.7%)报告严重不良事件,各组间无差异,其中3例被因果委员会判定为疫苗产品相关。
  • 研究期间发生6例死亡,均与疫苗无因果关联。

临床怎么用

  • 本研究为9-23月龄儿童使用黄热病疫苗分剂接种提供了进一步安全性证据,但研究未针对安全性结局关联进行效能设计。

局限性

  • 研究未针对所监测的安全性结局关联进行效能设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lacking adequate safety data, the World Health Organization (WHO) recommends a full dose of yellow fever (YF) vaccine to children two years or younger. In older age groups in outbreak settings, the WHO recommends a fractional dose of YF due to vaccine shortages. Therefore, in children aged 9-23 months, we conducted a single-blind randomized controlled trial to compare the safety of fractional 1/2 and 1/5 doses of BioManguinhos 17DD YF vaccine with the full dose. This paper presents the final safety analysis for this trial. METHODS: At three study sites in Uganda, healthy children aged 9-23 months were recruited for inclusion. Data on adverse events following immunization (AEFI) was collected from March 26, 2019, to December 30, 2022, using active surveillance for 28 days post-vaccination. A diary card and a thermometer were used for the first 14 days post-vaccination. Serious adverse events (SAE) were investigated by an independent team from the Uganda AEFI committee. RESULTS: 1066 (60 %) of 1770 enrolled children reported at least one non-serious adverse event (NSAE), with the most reported events being fever 610 (34 %) and diarrhea 608 (34 %). Fever and diarrhea prevalence both peaked two days post-vaccination, and fever prevalence was statistically higher in the full dose group than either fractional dose group. Thirty (1.7 %) of participants reported a SAE, with no difference by study arm; this included three SAEs reported to be vaccine product-related by the causality committee. Although six deaths occurred during the study, none were causally associated with the vaccine. CONCLUSIONS: Our study did not identify any unexpected safety issues with the YF fractional or full dose vaccine and Vaccine-related SAEs were rare. Although our study was not powered to identify associations for the safety outcomes monitored, our findings provide further evidence on the safety of YF fractional dosing in children aged 9-23 months (NCT03725618).

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Lee SE, Najjengo M, Shaum A, et al. Adverse events following immunization (AEFI) with fractional one-fifth and one-half doses of yellow fever vaccine compared to standard dose in children 9-23 months old in Uganda, 2019-2022 - final report. Vaccine. 2026. PMID: 41512502. doi:10.1016/j.vaccine.2025.128131

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。